Roche Deal History & Licensing Activity
Roche is a large pharma headquartered in Switzerland. Over the past three years, Roche has been involved in 19 licensing and acquisition transactions, with a primary focus on Small Molecules (7 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
13
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Roche Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Roche in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Atavistik Bio cardiovascular, renal, and metabolic disease research collaboration | Atavistik Bio | Other | Discovery | collaboration | Sep 24, 2026 |
| Bispecific antibodies for immune and inflammatory diseases | Dualitas Therapeutics | Bispecific Antibodies | Discovery | collaboration | Sep 17, 2026 |
| SIM0660 | Simcere Zaiming | Bispecific Antibodies | Unknown | license | Sep 1, 2026 |
| HM17321 | Genentech | Other | Preclinical | license | Aug 24, 2026 |
| IDE892 + GDC-7035 (RG6620) | Genentech | Small Molecules | Phase 1 | collaboration | Aug 19, 2026 |
| Breast cancer therapy research program | Genentech | Small Molecules | Discovery | collaboration | Jul 6, 2026 |
| breast cancer program | Astex Pharmaceuticals | Small Molecules | Discovery | collaboration | Jul 6, 2026 |
| bexobrutideg (NX-5948) | Nurix Therapeutics | Small Molecules | Unknown | collaboration | Jun 8, 2026 |
| Undisclosed | SangeneBio | Oligonucleotides | Discovery | license | Feb 3, 2026 |
| YL201 | MediLink Therapeutics | ADC | Preclinical | license | Jan 8, 2026 |
Showing 10 of 12 recent transactions. Upgrade to Pro for full deal history with financials.
Roche Pipeline Focus
Therapeutic areas and modalities where Roche is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Roche Strategic Signals
Key indicators of Roche's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Roche Clinical Pipeline
Roche has 50 active clinical trials across 7 development phases.
1
Phase 4
2
Unknown
3
Not Applicable
20
Phase 1
3
Phase 1/2
13
Phase 2
8
Phase 3
See How Your Asset Matches Roche's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Roche Licensing & Deal Activity
Roche is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 19 deals over the past three years, Roche ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Roche include Solid Tumors (20 deals and trials), Oncology (12 deals and trials), Other (6 deals and trials), and Neurology (6 deals and trials). In terms of modality, Roche has shown particular interest in small molecules, bispecific antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Roche and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Roche's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.